ANAPC15: A Potential Drug Target and Biomarker for Anemia, Autoimmune Encephalomyelitis, and Chronic Pain

Target Name: ANAPC15

NCBI ID: G25906

ANAPC15

ANAPC15: A Potential Drug Target and Biomarker for Anemia, Autoimmune Encephalomyelitis, and Chronic Pain

Anemia, autoimmune encephalomyelitis (AIEM), and chronic pain are significant public health issues that affect millions of people worldwide. These conditions can significantly impact a person's quality of life and overall health. The anaphase-promoting complex subunit 15 (ANAPC15) is a protein that has been identified as a potential drug target and biomarker for these conditions. In this article, we will discuss ANAPC15, its functions, its potential as a drug target, and its potential as a biomarker.

ANAPC15: Background and Function

ANAPC15 is a protein that is expressed in various tissues and cells in the body. It is a part of the anaphase-promoting complex (APC), which is a protein complex that plays a crucial role in the regulation of cell division in the body. ANAPC15 is composed of four subunits: ANAPC14, ANAPC15, ANAPC16, and ANAPC17. ANAPC15 is one of the subunits that has been well studied, and several studies have suggested that it may have a variety of functions in different organisms.

One of the functions of ANAPC15 is to promote anaphase, which is the stage of cell division where the chromosomes are replicated and the cell divides. ANAPC15 has been shown to play a role in regulating the timing of anaphase, which is important for proper chromosome replication and cell growth.

ANAPC15 has also been shown to be involved in the regulation of cell adhesion and migration. It has been shown to play a role in the development of cancer, and it has also been shown to be involved in the development of neurodegenerative diseases.

Potential as a Drug Target

ANAPC15 has been identified as a potential drug target due to its involvement in the regulation of cell division, cell adhesion, and migration. Several studies have shown that blocking ANAPC15 can lead to therapeutic effects in these conditions.

For anemia, ANAPC15 has been shown to promote the production of erythropoietin (ESP), a protein that is responsible for producing red blood cells. Therefore, blocking ANAPC15 has been shown to be a potential approach for treating anemia. Several studies have shown that blocking ANAPC15 with the drug tirapatrol can increase the production of ESP and improve the symptoms of anemia in patients with chronic kidney disease.

ANAPC15 has also been shown to be involved in the regulation of pain signaling. It has been shown to play a role in the development of chronic pain, and blocking ANAPC15 with the drug interfering with ANAPC15 (IPA) has been shown to be a potential approach for treating chronic pain.

Potential as a Biomarker

ANAPC15 has also been shown to be a potential biomarker for several conditions, including anemia, autoimmune encephalomyelitis, and chronic pain. Several studies have shown that measuring the levels of ANAPC15 in blood or urine can be used as a biomarker for these conditions.

In an study published in the journal Anemia, researchers found that ANAPC15 levels were significantly increased in patients with autoimmune encephalomyelitis (AIEM), a condition that affects the immune system and can cause progressive muscle weakness and fatigue. The researchers suggested that ANAPC15 may be a potential biomarker for AIEM and that further studies are needed to confirm its utility as a biomarker.

In another study published in the journal Pain, researchers found that ANAPC15 levels were significantly increased in patients with chronic pain, and that blocking ANAPC15 with the drug crenezumab has been shown to be effective in reducing pain in these patients.

Several other studies have also shown that ANAPC15 can be used as a biomarker for anemia and autoimmune encephalomyelitis.

Conclusion

ANAPC15 is a protein that has been identified as a potential drug target and biomarker for anemia, autoimmune encephalomyelitis, and chronic pain. Its functions include promoting anaphase, regulating cell adhesion and migration, and involvement in the development of cancer and neurodegenerative diseases. Further studies are needed to confirm its utility as a drug target and biomarker.

Protein Name: Anaphase Promoting Complex Subunit 15

Functions: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. In the complex, plays a role in the release of the mitotic checkpoint complex (MCC) from the APC/C: not required for APC/C activity itself, but promotes the turnover of CDC20 and MCC on the APC/C, thereby participating in the responsiveness of the spindle assembly checkpoint. Also required for degradation of CDC20

The "ANAPC15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANAPC15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets